Nanobiotix: Baillie Gifford falls below 5% of share capital
The declarant stated that it held 1,739,697 Nanobiotix shares representing the same number of voting rights, i.e. 4.99% of the capital and 4.79% of the voting rights of this biotech company specializing in radiotherapy to combat cancer.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction